Article

Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trial

2025-08-04

Abstract excerpt

<title>Abstract</title> <p>Patients with oestrogen receptor-positive (ER+), HER2-negative, early breast cancer (BC) have low pathological complete response (pCR) rates following neoadjuvant chemotherapy (NACT). Phase 3 trials showed that adding an anti-PD-1 immune checkpoint inhibitor (ICI) improves pCR, but there was less benefit in the PD-L1 negative tumours, characterised by an immune “cold” tumour microenviro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 515cbbaa-71cf-5358-868f-6c889e996910
DOI: 10.21203/rs.3.rs-7159624/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trialDOI 10.21203/rs.3.rs-7159624/v1Read

CHA1: A New Combinatorial Therapy That Reciprocally Regulates Wnt and JAK/STAT/Interferon Signaling to Re-program Breast Tumors and the Tumor-Resident LandscapeSemantic proximity Read

Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast CancersSemantic proximity Read

Radiosensitivity is associated with antitumor immunity in estrogen receptor-negative breast cancerSemantic proximity Read

Magnetic field-induced ER stress reprograms the tumor microenvironment to improve triple-negative breast cancer survivalSemantic proximity Read

Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH-positive early- stage breast cancer: A retrospective multicenter cohort studySemantic proximity Read

Neoadjuvant anti-4-1BB confers protection against spontaneous metastasis through low-affinity intratumor CD8 <sup>+</sup> T cells in triple-negative breast cancerSemantic proximity Read

Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives.Semantic proximity Read

A phase Ib trial evaluating the safety, efficacy, and immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancerSemantic proximity Read

Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple Negative Breast CancerSemantic proximity Read

Mid-treatment radiologic response as an early predictor of pathologic response in TNBC in the era of pembrolizumabSemantic proximity Read

Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumabSemantic proximity Read

Microtubule targeting agents influence the clinical benefit of immune response in early breast cancerSemantic proximity Read